Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Council Members who Treat Colon/Colorectal Cancer

Articles with lock require a subscription to GLG News | Request a free trial
October 21, 2008
GVAX: Why did it fail? Let me list the possible ways......
Analysis of: Cell Genesys Announces Termination of VITAL-1 Phase 3 Trial of GVAX Immunotherapy for Prostate Cancer | pharmalive.com
Author: GLG Expert Contributor
Cell Genesys is basically stopping work on GVAX inview of failure in two trials. The cause of the failure is not readily apparent.
Donald FlemingOctober 20, 2008
We must hit the cancer target by genetics or whatever technique
Analysis of: Genetic Research May Help Pick Patients' Best Cancer Drugs | online.wsj.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Targeted therapy for cancer is the new trend Targeted therapy will allow the use of more expensive drugs to be more practical We need to focus on hitting a target more than ever
Donald FlemingOctober 20, 2008
Government Run Cancer care
Analysis of: Roche Cuts Price of Cancer Drug | online.wsj.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
There has been distubing trends in nationalized health care in regrds to cancer care Recently the UK made an absolutely shocking decision on renal cancer therapy, as it has in other cancers in the past Hopefully through advances in predicting cancer therapy outcomes via microarray etc. we can...
October 15, 2008
Thyroid cancer: When it rains it pours
Analysis of: Phase II Trial of Sorafenib in Advanced Thyroid Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
 as per an accompanying editorial "In conclusion, it is particularly gratifying that years of research in tumor biology and drug development have coalesced. Translation of these research advances into therapeutic benefits for patients with refractory thyroid cancer, and a related paradigm shift...
October 15, 2008
Genetically determined cancer therapy: It will be a wash.
Analysis of: Genetic Research May Help Pick Patients' Best Cancer Drugs | online.wsj.com
Author: GLG Expert Contributor
Genetic determinants will decrease use of some drugs due to mutations such as Kras which indicate less chance of response and thus the chemo agents will not be used.
Donald FlemingOctober 9, 2008
Beta trial negative, but is it truely blinded
Analysis of: Genentech Set Back by Cancer-Drug Study | online.wsj.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Beta trial implies that Avastin adds to the effectiveness of the other Genentech drug, Tarceva There is an attempt to change treatment gudelines in second line non small treatment
October 8, 2008
Avastin/Tarceva/Roche/OSI/Genentech: So much for "synergy" in lung cancer
Analysis of: Genentech Set Back by Cancer-Drug Study | online.wsj.com
Author: GLG Expert Contributor
The primary goal was improved survival- NOT REACHED!!
October 6, 2008
Government Intervention is Here: Pharma had better get use to it....
Analysis of: Roche Cuts Price of Cancer Drug | online.wsj.com
Author: GLG Expert Contributor
"U.K. Health Service Agrees to Pay for Tarceva Following the Company's Discount" so that the price is equivalent to Taxotere.
October 3, 2008
Radon & Lung cancer: Outside of Uranium Mines is it Relevant???
Analysis of: Protecting a Home From Silent Threat | www.nytimes.com
Author: GLG Expert Contributor
Radon is responsible for about 15% on lung cancer deaths in the US??
October 2, 2008
Idera Pharma: is there room for another agent in recurrent renal cell ca??
Analysis of: Idera Pharmaceuticals Announces Preliminary Data from Phase 2a Clinical Study of IMO-2055 Monotherapy in Renal Cell Carcinoma | www.pipelinereview.com
Author: GLG Expert Contributor
Apparently Merck has an interest in this compound and it is in trial in combination in other neoplasms.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 Next21 to 30 of 660

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T17:45:17.163